ProCE Banner Activity


CAR T-Cell Therapy: Expert Guidance for Community Practice

In this on-demand webcast from a live meeting, oncology expert Jesús G. Berdeja, MD, discusses current best practices in the use of CAR T-cell therapy to treat patients with hematologic malignancies.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit 

Released: October 26, 2022

Expiration: October 25, 2023

No longer available for credit.



Jesus G. Berdeja

Jesus G. Berdeja, MD

Director, Multiple Myeloma Program
Sarah Cannon Research Institute
Attending Physician
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Bristol Myers Squibb

Novartis Pharmaceuticals Corporation

Target Audience

This program is intended for hematologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with hematologic malignancies who may benefit from or who have received CAR T-cell therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Recall the scientific principles underlying the use of CAR T-cells
  • Identify patients who are likely to benefit from CAR T-cell therapy and refer to the appropriate authorized center for treatment or clinical trial enrollment
  • Determine best practices for timely referral of appropriate patients for CAR T-cell therapy and develop proper channels of communication between community and academic centers to streamline the logistics of delivering therapy
  • Apply multidisciplinary interventions to monitor, identify, and manage acute toxicities and ensure patient safety while receiving CAR T-cell therapy
  • Integrate recent developments, clinical trial findings, and indications of recently approved and emerging CAR T-cell therapies into clinical practice to enhance clinical outcomes


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Jesus G. Berdeja, MD

Director, Multiple Myeloma Program
Sarah Cannon Research Institute
Attending Physician
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Jesús G. Berdeja, MD: researcher: AbbVie, Acetylon, Amgen, Astex, Bluebird bio, BMS, CARsgen Therapeutics, Cartesian Therapeutics, Celator, Celgene, Celularity, CRISPR, CURIS, C4 Therapeutics, EMD Serono, Fate Therapeutics, Genentech, GSK, Ichnos Sciences, Incyte, Janssen, Juno, Karyopharm, Kesios, Lilly, Millennium, Novartis, Onyx, Pharmacyclics, Poseida, Sanofi, Takeda, Vivolux.

Staff Disclosure


Kayla Douglas, PharmD

Director of Pharmacy
Mississippi Center for Advanced Medicine
Madison, Mississippi

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN: speaker: AstraZeneca, Bristol-Myers Squibb, DSI, Gilead, Lilly, Morphosys, Pfizer, Regeneron.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC

Jacqueline L. Olin, MS, PharmD, BCPS, FASHP, FCCP, has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping has no relevant financial relationships to disclose.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant financial relationships to disclose.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-266-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 26, 2022, through October 25, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this activity is to improve the knowledge, competence, and performance of clinicians practicing in community settings managing patients eligible for, or who have received CAR T-Cell therapy.